Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1988 1
1989 3
1991 4
1992 5
1993 5
1994 1
1995 4
1996 2
1997 3
1998 5
1999 3
2000 9
2001 4
2002 6
2003 7
2004 6
2005 4
2006 10
2007 8
2008 8
2009 7
2010 4
2011 5
2012 2
2013 2
2014 2
2015 2
2016 1
2017 3
2018 2
2019 1
2020 4
2021 7
2022 7
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

139 results

Results by year

Filters applied: . Clear all
Page 1
In Response.
Lee AJ, Huffmyer JL, Thiele EL, Zeitlin PL, Chatterjee D. Lee AJ, et al. Among authors: zeitlin pl. Anesth Analg. 2022 Jul 1;135(1):e7. doi: 10.1213/ANE.0000000000006032. Epub 2022 Jun 16. Anesth Analg. 2022. PMID: 35709461 No abstract available.
Cystic fibrosis.
Rosenstein BJ, Zeitlin PL. Rosenstein BJ, et al. Among authors: zeitlin pl. Lancet. 1998 Jan 24;351(9098):277-82. doi: 10.1016/S0140-6736(97)09174-5. Lancet. 1998. PMID: 9457113 Free article. Review. No abstract available.
Prognosis in cystic fibrosis.
Rosenstein BJ, Zeitlin PL. Rosenstein BJ, et al. Among authors: zeitlin pl. Curr Opin Pulm Med. 1995 Nov;1(6):444-9. doi: 10.1097/00063198-199511000-00003. Curr Opin Pulm Med. 1995. PMID: 9363080 Review.
The Precision Interventions for Severe and/or Exacerbation-Prone (PrecISE) Asthma Network: An overview of Network organization, procedures, and interventions.
Georas SN, Wright RJ, Ivanova A, Israel E, LaVange LM, Akuthota P, Carr TF, Denlinger LC, Fajt ML, Kumar R, O'Neal WK, Phipatanakul W, Szefler SJ, Aronica MA, Bacharier LB, Burbank AJ, Castro M, Crotty Alexander L, Bamdad J, Cardet JC, Comhair SAA, Covar RA, DiMango EA, Erwin K, Erzurum SC, Fahy JV, Gaffin JM, Gaston B, Gerald LB, Hoffman EA, Holguin F, Jackson DJ, James J, Jarjour NN, Kenyon NJ, Khatri S, Kirwan JP, Kraft M, Krishnan JA, Liu AH, Liu MC, Marquis MA, Martinez F, Mey J, Moore WC, Moy JN, Ortega VE, Peden DB, Pennington E, Peters MC, Ross K, Sanchez M, Smith LJ, Sorkness RL, Wechsler ME, Wenzel SE, White SR, Zein J, Zeki AA, Noel P; PrecISE Study Team. Georas SN, et al. J Allergy Clin Immunol. 2022 Feb;149(2):488-516.e9. doi: 10.1016/j.jaci.2021.10.035. Epub 2021 Nov 29. J Allergy Clin Immunol. 2022. PMID: 34848210 Free PMC article. Review.
Emerging drug treatments for cystic fibrosis.
Zeitlin PL. Zeitlin PL. Expert Opin Emerg Drugs. 2007 May;12(2):329-36. doi: 10.1517/14728214.12.2.329. Expert Opin Emerg Drugs. 2007. PMID: 17604505 Review.
Atypical cystic fibrosis and CFTR-related diseases.
Paranjape SM, Zeitlin PL. Paranjape SM, et al. Among authors: zeitlin pl. Clin Rev Allergy Immunol. 2008 Dec;35(3):116-23. doi: 10.1007/s12016-008-8083-0. Clin Rev Allergy Immunol. 2008. PMID: 18493878 Review.
139 results